Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Irving

Showing results (171-180 of 195) with videos related to

Pageof 20
Sort By:
Frontline Gastroenterology|September 3, 2020
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemicNicholas A Kennedy, Richard Hansen, Lisa Younge, et al.
Gastroenterology|October 11, 2019
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's DiseaseAleksejs Sazonovs, Nicholas A Kennedy, Loukas Moutsianas, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Gastroenterology|November 3, 2015
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative ColitisGaik W Tew, Jason A Hackney, Deena Gibbons, et al.
Gut|April 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDNicholas A Kennedy, Simeng Lin, James R Goodhand, et al.
Journal of Crohn'S & Colitis|September 2, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated PatientsNeil Chanchlani, Simeng Lin, Desmond Chee, et al.
Gut|February 8, 2023
Considerations for peripheral blood transport and storage during large-scale multicentre metabolome researchJames L Alexander, Nicola J Wyatt, Stephane Camuzeaux, et al.
Journal of Crohn'S & Colitis|June 5, 2020
Clinical Features and Genetic Risk of Demyelination Following Anti-TNF TreatmentSimeng Lin, Harry D Green, Peter Hendy, et al.
The Lancet. Gastroenterology & Hepatology|March 3, 2019
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort studyNicholas A Kennedy, Graham A Heap, Harry D Green, et al.
Journal of Crohn'S & Colitis|December 28, 2018
Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort StudyMark A Samaan, Katrina Forsyth, Jonathan P Segal, et al.
Pageof 20

Showing results (171-180 of 195) with videos related to

Sort By:
Pageof 20
Frontline Gastroenterology|September 3, 2020
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemicNicholas A Kennedy, Richard Hansen, Lisa Younge, et al.
Gastroenterology|October 11, 2019
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's DiseaseAleksejs Sazonovs, Nicholas A Kennedy, Loukas Moutsianas, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Gastroenterology|November 3, 2015
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative ColitisGaik W Tew, Jason A Hackney, Deena Gibbons, et al.
Gut|April 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDNicholas A Kennedy, Simeng Lin, James R Goodhand, et al.
Journal of Crohn'S & Colitis|September 2, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated PatientsNeil Chanchlani, Simeng Lin, Desmond Chee, et al.
Gut|February 8, 2023
Considerations for peripheral blood transport and storage during large-scale multicentre metabolome researchJames L Alexander, Nicola J Wyatt, Stephane Camuzeaux, et al.
Journal of Crohn'S & Colitis|June 5, 2020
Clinical Features and Genetic Risk of Demyelination Following Anti-TNF TreatmentSimeng Lin, Harry D Green, Peter Hendy, et al.
The Lancet. Gastroenterology & Hepatology|March 3, 2019
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort studyNicholas A Kennedy, Graham A Heap, Harry D Green, et al.
Journal of Crohn'S & Colitis|December 28, 2018
Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort StudyMark A Samaan, Katrina Forsyth, Jonathan P Segal, et al.
Pageof 20